Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

April 11, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

February 7, 2022

Conditions
Coronavirus Disease 2019 COVID-19
Interventions
DRUG

TJ003234

patients receive a single infusion

DRUG

Placebo

patients receive a single infusion

Trial Locations (14)

20007

Georgetown University Hospital, Washington D.C.

20037

The GW Medical Faculty Associates, Washington D.C.

33146

University of Miami, Miami

39216

University of Mississippi Medical Center, Jackson

46202

Indiana University Health, Indianapolis

61637

OSF Healthcare Saint Francis Medical Center, Peoria

70006

Medpharmics, LLC, Metairie

70121

Ochsner Medical Center, New Orleans

72205

University of Arkansas, Little Rock

77030

Houston Methodist Hospital, Houston

87106

UNM Hospitals, Albuquerque

89102

University Medical Center of Southern Nevada, Las Vegas

91342

Olive View-UCLA Medical Center, Sylmar

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
lead

I-Mab Biopharma US Limited

INDUSTRY